Status: Recruiting
Safety, Tolerance and Antiretroviral Activity of Dasatinib: a Pilot Clinical Trial in Patients With Recent HIV-1 Infection
Study to evaluate the safety, tolerability and antiretroviral activity of a new therapeutic strategy, based on the administration of dasatinib, an ITK, in patients with recent (3-12 months) asymptomatic HIV-1 infection.
Participants needed: 24
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Eva BonfillUpdated: May 1, 2025Locations: 1
Eligibility criteria
18 to 65 years. [+4]
Active HBV (HBsAg+ or DNA+) and/or HCV (RNA+) infection in screening. [+8]